You’re using a public version of DrugChatter with 1 free searches available. Register to unlock more free searches per day. CREATE FREE ACCOUNT

Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

In what ways does ozempic influence appetite?

Ozempic, also known as semaglutide, is a glucagon-like peptide-1 (GLP-1) receptor agonist used to improve glycemic control in adults with type 2 diabetes. According to the drug's prescribing information, Ozempic can influence appetite in several ways [1]:

1. Delayed gastric emptying: Ozempic slows down the rate at which the stomach empties after eating, which can lead to a feeling of fullness and reduced appetite [1].

2. Central appetite regulation: GLP-1 receptors are present in several areas of the brain that regulate appetite and food intake. Activation of these receptors by Ozempic can result in reduced hunger and appetite, leading to decreased food consumption [1][2].

3. Weight loss: As a result of reduced appetite and calorie intake, Ozempic has been shown to cause weight loss in some patients. In clinical trials, patients taking Ozempic experienced an average weight loss of 4.5-6.2 kg (9.9-13.7 lbs) over a 26-56 week period, depending on the dosage [1].

It is important to note that individual responses to Ozempic may vary, and not all patients will experience the same effects on appetite and weight loss. Patients should consult their healthcare provider for personalized advice regarding the use of Ozempic and its potential impact on appetite [1].

[1] Novo Nordisk. Ozempic (semaglutide) injection, for subcutaneous use. Prescribing Information. 2021. <>
[2] Ozempic. <>
[3] Ozempic (semaglutide) - Patent Expiration & Drug Sales Data. <>

Follow-up:   How does Ozempic regulate appetite hormones? What role does Ozempic play in reducing food cravings? Can Ozempic's appetite control help with weight loss?

DrugPatentWatch - Make Better Decisions
© thinkBiotech LLC 2004 - 2024. All rights reserved.